{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Deep venous thrombosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Pulmonary embolism"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.","groups":[{"description":"Received dalteparin 5000 units daily postop, patients with metastatic disease.","id":"OG000","title":"Interventional (Dalteparin, Metastatic)"},{"description":"Received dalteparin 5000 units daily postop, patients with primary sarcomas.","id":"OG001","title":"Interventional (Dalteparin, Sarcoma)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 weeks after surgery","title":"Number of Participants With Occurrence of Venous Thromboembolism","type":"SECONDARY","unitOfMeasure":"Participants"}